Bruce Clark

Chief Executive Officer

Mr. Clark leads the Nirvana team, seeking new solutions to one of our society’s most confounding issues. He sees great potential in the opportunity to development of new approaches to a complex problem which is both a public health and economic issue for our communities. Mr. Clark is a proven innovator who brings 30 years management experience across a variety of industries, including energy, food and beverage manufacturing and life science. He possesses broad experience in product development, manufacturing and product distribution and a clear understanding of the regulatory process. He has a deep understanding of the public policy issues at play and the importance of collaboration with all levels of government and health professionals through the development process.

Connie Hang

Chief Financial Officer

Ms. Hang has over 20 years of finance, accounting, and management experience in a variety of industries, including energy, mining, and health science.

In the past 12 years Ms. Hang has acted as an advisor, officer and/or director for various public and private companies, which span across Canadian based companies to foreign controlled entities.

From 1999 to 2009, Ms. Hang worked in professional accounting firms and held senior positions in tax and audit practices.

Having served over 40 public and private companies, which span across Canadian based companies to foreign controlled entities, she has gained in- depth knowledge of financial and regulatory affairs.

Her experience in dealing with people from different cultures and disciplines has solidified her ability to understand the needs of stakeholders and communicate complex ideas.

Ms. Hang is a Member of the Chartered Professional Accountants of Canada and British Columbia and holds a Bachelor of Accounting Science from University of Calgary.

Dr. Sazzad Hossain

Chief Scientific Officer

Dr. Hossain is the former Chief Scientific Officer of InMed Pharmaceuticals Inc., a leading public Canadian bio-pharmaceutical company.

Previously he worked as Senior Scientist at Biotechnology Research Institute of National Research Council Canada.

Dr Hossain is a drug discovery leader over 15 years of biotech/pharmaceutical experience with small molecule & biologics in multiple disease indications.

He has experience in accelerated drug discovery and commercialization process with combined experience in preclinical in vivo pharmacology, DMPK, safety & toxicology.

He has led teams in the strategic design of new natural health products and generated hundreds of millions of dollars in revenue by leading development of multiple successful compounds.

Dr Hossain holds a PhD in Biology and was a post doctoral Fellow at the Centre for Molecular Medicines and Therapeutics at the University of BC

Robert August IV

Head of Innovation

Robert began his academic career at Loyola University in Baltimore, Maryland. During his undergraduate years, Robert worked as an analytical chemist for Martel Laboratories where he received his state analytical certifications for ICP, GC/MS and LC/MS operations. While pursuing a post graduate degree in medicinal chemistry at Johns Hopkins University, Robert turned his focus toward the synthesis of psychoactive and psychedelic compounds, namely ergolines such as LSD and phenethylamines like MDMA and 2CB.

It is during this time that Robert began to work as a research chemist and, eventually, began to actively pursue working partnerships with other chemists who were researching psychedelic compounds like Dr. David E. Nichols and Nick Sand with whom Robert worked with briefly in Vancouver, B.C.

After earning a reputation as a skilled chemist, Robert was invited to work alongside Ben Alkire (Purdue University) in Lafayette, Indiana where he went on to cofound Berkeley-Clearlight Research Group.

While forming BCRG, Robert was given unlimited access to the D.E. Nichols Archive at Purdue University and the vast array of synthesis notes created by Dr. Oberlender during his time as a chemist for the Nichols team.

In the years that followed, Robert synthesized numerous novel compounds and research chemicals and became the first person to synthesize 3,4-MDMA Monohydrate HCl as a crystalline solid and as a beta ketone. Robert is a highly respected member of the psychedelic community and an advocate for ending prohibition.

Michael McCune

Vice President Operations

Mr. McCune is a seasoned entrepreneur and innovator in the extraction space.

Since 2013, he has applied his passion for science to developing novel processes for producing API’s for Cannabis industry. He has built a specialty for at-scale extraction of a wide variety of materials.
He led the development of a leading-edge distillation system that offers significant operational advantages and automation. He has overseen the development, trials and contract manufacture of this system.

Michael is recognized as a lead leader in these technologies and has co-authored several Patents. He maintains a global network and has presented at numerous conferences on the topics of Extraction and Cannabis Technologies.